| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fdaffe64e0056ceff97698a913ed913 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18845
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18832
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-40 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6901
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 |
| filingDate |
2003-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9e986f556ef6126034d39bedd382118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f8e7f945203c29f1765a3a065912c00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44a1d138e7014d14e79991efdf285f31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95a25092e4d74379b777d44b4a7bcf8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff142631b6b8fb24481df59bdb55c235 |
| publicationDate |
2003-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2484287-A1 |
| titleOfInvention |
Pharmaceutical- or gene-carrier compositions with reduced hemagglutinating activity |
| abstract |
It is intended to provide a drug- or gene-carrier composition having a lower ed hemagglutinin activity. A drug- or gene-carrier composition having a lowered hemagglutinin activity (compared to the case without the addition) can be successfully constructed by adding a compound to an envelope protein having a hemagglutinin activity of a minus strand RNA virus. For example, a virus vector provided in an embodiment shows significantly lowered erythrocyte agglutination activity and hemolytic activity and thus the stability of the vector in blood is remarkably elevated. The drug- or gene-carrier compositio n thus provided can be adequately used in transferring a drug or a gene into a living body. |
| priorityDate |
2002-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |